Tag Archives: Allergan PLC

Teva stock crashes on 2Q earnings disaster; run for the hills, or buy at fire sale price?

The News: Teva Pharmaceutical Industries Ltd., which has been without a permanent CEO for six months, plunged $11.74, or 36% last week, to $20.60–the most in almost two decades. The… Read more »



Update: CDC data say docs still making billions from Pharma, med device companies; my personal take.

The News: It’s been a few years since the US government unveiled its Open Payments (OP) database, a collection of drug and device makers’ payments to healthcare providers. The data-collection… Read more »



Novartis teams up with Allergan in NASH gamble; heated race to riches in full swing

The News: Allergan PLC (Dublin IRL) is expanding its research and development program on non-alcoholic steatohepatitis (NASH) through a collaboration with Novartis AG (Basel CHE) that will test a new… Read more »



Week’s opening stock salvo: Cellect, Impax, Cancer Genetics celebrate; Foamix, not so much

After the resounding thud heard round-the-world Friday upon the failure of Trumpcare, healthcare stocks were back in vogue with investors Monday (March 27, 2017). Here are the top stars and… Read more »



Trump tweet on drug prices sinks pharma shares; what’s next, doctors’ wages? Not.

Steve’s Take: President Trump’s morning ritual continues to enthrall millions, but occasionally causes Wall Street analysts covering the pharma industry to reach for their bottle of Maalox. After House Republicans… Read more »



After Trump’s charge of “getting away with murder,” J&J, other Pharmas scramble to tout price restraints; but who’s kidding whom?

Steve’s Take: I thought the pharma business, like any other, was built on the bedrock precept of: charge what the market will bear, until you’re forced to pull back the… Read more »



Teva reports 4Q earnings surprise; but 2017 guidance seen “through a glass darkly.”

The News: Teva Pharmaceutical Industries Ltd. (Petach Tikva ISR) reported Monday (February 13, 2017) that fourth-quarter sales surged 33% year-over-year to $6.5 billion, topping analysts’ estimates of $6.3 billion. The company… Read more »



Allergan wraps up 2016 M&A with LifeCell buy for $2.9 billion; analysts lavish kudos all around

Dublin-based Allergan said on December 19, 2016 it would buy LifeCell, a regenerative medicine unit owned by privately held Acelity LP (San Antonio TX), for $2.9 billion in cash, bringing… Read more »



New Biogen pick for CEO inherits tough job; markets aren’t exactly enthralled–yet

Biogen Inc. (Cambridge MA) said Monday (December 19, 2016) it has named veteran biopharmaceutical executive Michel Vounatsos, head of the company’s commercial organization, its next chief executive. Mr. Vounatsos will succeed George Scangos, who announced earlier this… Read more »



Feds charge Heritage execs with price fixing; DOJ ringing out 2016 on a roll against Pharma offenses

The former chief executive and former president of generic drug company Heritage Pharmaceuticals Inc. (Eatontown, NJ) have been charged with conspiring to fix prices, the first charges in a continuing… Read more »